OpenEvidence, the Boston-based startup that has quietly emerged as one of the most promising AI companies in clinical medicine, has achieved a $1.2 billion post-money valuation in its latest funding round a doubling from its previous mark. The round, finalised in mid-January 2026, drew strong participation from leading healthcare investors, technology-focused funds, and strategic partners who see OpenEvidence as a foundational layer for the future of evidence-based practice.

Founded by clinicians and AI researchers from Harvard Medical School and MIT, OpenEvidence has built a specialised large language model trained exclusively on high-quality medical literature, clinical guidelines, treatment protocols, drug databases, and real-world evidence sources. Unlike general-purpose models, OpenEvidence is engineered for accuracy, citations, and transparency every response includes traceable references to primary sources, reducing hallucination risk and enabling physicians to verify information instantly.

The platform is designed as a “clinical companion” for doctors: it answers complex diagnostic, therapeutic, and management questions in seconds, supports literature reviews, generates differential diagnoses, summarises guidelines, and assists with treatment planning. Early adopters primarily academic physicians and specialists in oncology, cardiology, infectious diseases, and internal medicine report significant time savings and increased confidence in decision-making, particularly for rare or rapidly evolving conditions.

The rapid valuation increase reflects several converging factors: growing demand for trustworthy AI in medicine amid rising clinician burnout, increasing regulatory clarity around clinical decision support tools, and mounting evidence that specialised medical LLMs outperform general models on clinical reasoning benchmarks. OpenEvidence has consistently ranked at or near the top of MedQA-style evaluations while maintaining near-perfect citation accuracy.

The new capital will be used to:

Expand the corpus to include more global guidelines and non-English literature

Develop multimodal capabilities (interpreting radiology, pathology images, and genomic reports)

Scale enterprise deployments in hospitals and health systems

Invest in regulatory validation and compliance pathways for broader clinical use

Grow the team in engineering, clinical informatics, and medical content curation

CEO and Co-founder Dr. Daniel Nadler emphasised the company’s mission: “We built OpenEvidence because physicians need fast, reliable answers grounded in the full breadth of medical knowledge not generic chatbots or unverified summaries. This funding allows us to deepen our clinical utility and reach more doctors at the point of care.”

The $1.2 billion valuation places OpenEvidence among the most highly valued private medical AI companies globally and signals strong market belief in specialised, domain-specific models over general-purpose large language models for high-stakes clinical applications.

With this latest round, OpenEvidence is well-positioned to expand its footprint in academic medical centres, community hospitals, and international markets while continuing to raise the bar for accuracy, transparency, and clinical relevance in AI-assisted medicine.